But they were reluctant to promise to cut list prices without other reforms.
Multiple senators questioned AbbVie CEO Richard A. Gonzalez about how the company set the price of the arthritis drug Humira.
The list price of the drug more than doubled over six years and now costs more than $60,000 per year.
"So taxpayers subsidize your research, subsidize your marketing and you continue to raise drug list prices on them," the Ohio Democrat said.
The drug industry and its main lobbying group, the Pharmaceutical Research and Manufacturers of America, have resisted efforts to curb drug prices.